The Motley Fool
23 Aug 2026, 11:15 UTC · 2h ago
Why Tempus AI Skyrocketed This Week
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
23 Aug 2026, 11:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Merck and Moderna's Phase 3 trial showed that a combined mRNA cancer vaccine and Keytruda treatment significantly diminished cancer return and spread compared to Keytruda alone. — Successful Phase 3 results for a cancer vaccine are a major clinical milestone that creates significant value for the developers and the broader oncology market.
+0.80Tempus AI is in a binding agreement to acquire Personalis, the developer of the genomic tumor-profiling technology used in the Merck and Moderna vaccine trials. — This acquisition directly links Tempus AI to the successful trial results, providing a clear growth catalyst and technological validation.
+0.60Tempus AI stock rose 39.5% over the previous week, diverging from a declining S&P 500 and Nasdaq. — Strong relative strength indicates high investor confidence in the specific catalyst despite broader market valuation pressures.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Stock posted massive gains following positive trial results for technology it is acquiring via Personalis.
Positive Phase 3 trial data for a jointly developed cancer vaccine showed significant benefits for patients.
Positive Phase 3 trial data for a jointly developed cancer vaccine showed significant benefits for patients.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
58m ago
